Etoposide (VP-16-213)
- 1 June 1979
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 6 (2), 107-124
- https://doi.org/10.1016/s0305-7372(79)80045-6
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agentsGynecologic Oncology, 1978
- EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN TREATMENT OF SOLID TUMOURSThe Lancet, 1977
- Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)Cancer, 1977
- Evaluation of VP-16 and the Combination of Adriamycin and Vincristine in Advanced Breast CancerOncology, 1976
- Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.BMJ, 1975
- EPEG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.BMJ, 1975
- Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxinJournal of Medicinal Chemistry, 1971
- Human anticancer effect of podophyllum derivatives (SPG and SPI): a preliminary report.British Journal of Cancer, 1967